We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Video

Regulation of antibody immunotherapy by fine-tuning FcR interactions

Rectangle Image
Video

Regulation of antibody immunotherapy by fine-tuning FcR interactions

About the Speaker


Mark Cragg is a Professor in Experimental Cancer Biology at the Cancer Sciences Division of Southampton University School of Medicine, UK. He obtained his PhD in 1998 and did his postdoctoral studies with Martin Glennie in Southampton and then Andreas Strasser at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. He has published over 60 papers, many in high impact journals such as the Journal of Clinical Investigation, PNAS, Plos Medicine and Blood and leads a dynamic research group interested in all aspects of how therapeutics such as antibodies result in tumour regression and how they can be improved.
Abstract

Monoclonal antibodies (mAb) represent a growing class of ‘block-buster’ cancer drugs and so understanding of their modes of action is critical. Here, we present evidence that different mAb interact with Fc receptors differently in order to achieve their therapeutic activities.

Advertisement